KR101988850B1 - Composition comprising astrocyte elevated gene-1 for preventing or treating epilepsy - Google Patents

Abstract

The present invention relates to a composition for preventing or treating brain metastasis, which comprises an AEG-1 (astrocyte elevated gene-1) protein or a nucleic acid molecule encoding an AEG-1 protein as an active ingredient. In the present invention, it was confirmed that the AEG-1 treatment delayed the occurrence of epileptic seizures and the incidence of the epileptic seizures was reduced, and it was confirmed that granulocyte dispersion and mTORC1 (mammalian target of rapamycin complex 1) It is anticipated that a more fundamental approach to the prevention and treatment of bar and brain metastasis will enable targeted therapy.

Description

[0001] The present invention relates to a composition for preventing or treating epilepsy comprising AEG-1 as an active ingredient,

The present invention relates to a composition for preventing or treating brain metastasis, which comprises an AEG-1 (astrocyte elevated gene-1) protein or a nucleic acid molecule encoding an AEG-1 protein as an active ingredient.

Cerebral infarction is a disease that causes intermittent nervous system disturbance due to seizure discharge of brain cells due to organic or functional disorders and symptoms such as neurological symptoms, loss of consciousness, convulsions, and sensory disturbances. It is the third most common neurological disorder following Alzheimer's and Stroke, with about 0.5% to 2% of the world's population suffering from epilepsy. In addition, there are about 45 new cases per 100,000 people worldwide, and it is estimated that about 30 ~ 400,000 cases of epilepsy are present in Korea. According to the age distribution of patients with epilepsy, it is known that 70% of all epilepsy starts at the age of pediatric adolescence, especially in early childhood. In addition, the incidence and prevalence are the highest within 1 year after birth, fall sharply, show a suddenly increasing U-shape in elderly people over 60 years of age, and the prevalence of life-long seizures is 10 to 15%.

Epilepticus is a chronic disease in which epileptic seizures occur repeatedly. Its cause is very diverse, and the exact cause of it is unknown. However, recent developments in neuroimaging techniques have enabled us to observe microscopic pathological changes in the brain that could not be observed in the past, and the causes of brain metastasis are increasingly being identified. More than two-thirds of patients with epilepsy are idiopathic or latent with no specific cause, and the remaining cases are the cause of a serious cause to find the cause. In other words, if a neuropathologic change such as stroke, congenital anomaly, head trauma, encephalitis, brain tumor, degenerative encephalopathy, childbirth damage, central nervous system developmental disorder and genetic tendency or past history of brain damage, .

Unlike other brain diseases, granulosa cell differentiation is a neuropathologic feature that is commonly observed in the hippocampus of patients with temporal lobe epilepsy, and chronic epileptic seizures are caused by the abnormal cell formation of the hippocampus and granule cells. Although the cause of granular cell decidualization has not yet been clarified yet, recent studies have shown that hyperactivity of the mammalian target of rapamycin complex 1 (mTORC1), which is involved in cell growth and intrinsic / extrinsic cell signaling, It is associated with the development and progression of granular cell decidualization associated with evaporation. This shows that control of granule cell dispersal occurrence with mTORC1 activity inhibition can be associated with prevention and treatment of brain metastasis.

On the other hand, the treatment of brain metastasis can be divided into drug therapy and drug treatment, namely surgery, ketone diet, and vagus nerve stimulation. However, drug treatment has been used only for patients who are resistant to drugs, and medication has been used as a major method for treatment of brain tumors. Conventional medicines include Phenytoin (Dilantin®), Valproate (Orfil®, Depakine®, Depakote®), Carbamazepine (Tegretol®), Phenobarbital (Luminal®), ethosuccinimide (Topazamate), lamotrigine (Lamictal®), Vigabatrin (Sabril®), Oxcarbazepine (Trileptal®), and the like. Has been developed and commercialized.

Despite these drug treatments, more than 30% of epilepsy patients are drug refractory epilepsy, which does not control seizures, even with several mechanisms of action, Such as intractable skin rash caused by a reaction, gastrointestinal irritation caused by a drug, and dizziness, and there have been reported cases of causing psychiatric disorders and suicide by the use of drugs in the past. As a result, it is difficult to effectively treat epilepsy In fact. Therefore, studies on a new therapeutic agent for cerebral apoplexy have been actively conducted (Korean Patent Publication No. 10-2013-0065646).

Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made to solve the above-mentioned problems, and it is an object of the present invention to provide an AEG-1 (astrocyte elevated gene-1) protein or a nucleic acid molecule encoding the same, The delay effect was confirmed and the present invention was completed on the basis thereof.

Accordingly, an object of the present invention is to provide a pharmaceutical composition for preventing or treating brain metastasis, which comprises an astrocyte elevated gene-1 (AEG-1) protein or a nucleic acid molecule encoding the same.

Another object of the present invention is to provide a health functional food composition for improving brain metastasis comprising an astrocyte elevated gene-1 (AEG-1) protein or a nucleic acid molecule encoding the same.

In addition, another object of the present invention is to provide a method for screening a test substance (S1) for treating astrocyte elevated gene-1 (AEG-1) expression cell line;

Measuring the expression or activity level of AEG-1 in the cell line of step S1 (S2); And

(S3) the expression or activity level of AEG-1 in step S2 is higher than that of a control without treatment of the test substance.

However, the technical problem to be solved by the present invention is not limited to the above-mentioned problems, and other matters not mentioned can be clearly understood by those skilled in the art from the following description.

In order to accomplish the above object, the present invention provides a pharmaceutical composition for preventing or treating brain metastasis comprising, as an active ingredient, a nucleic acid molecule encoding an AEG-1 (astrocyte elevated gene-1) protein or an AEG-1 protein And a health functional food composition for preventing or ameliorating epilepsy.

In one embodiment of the present invention, the AEG-1 protein is characterized by being composed of the amino acid sequence shown in SEQ ID NO: 1.

In another embodiment of the present invention, the nucleic acid molecule encoding the AEG-1 protein is characterized by being composed of the nucleotide sequence shown in SEQ ID NO: 2.

In another embodiment of the present invention, the nucleic acid molecule encoding the AEG-1 protein is characterized by being contained in a vector.

In still another embodiment of the present invention, the vector is characterized by being at least one selected from the group consisting of linear DNA, plasmid DNA and recombinant viral vectors.

In another embodiment of the present invention, the recombinant viral vector is an adeno-associated virus (AAV).

In another embodiment of the present invention, the composition may inhibit the granulation of the granule cells.

In another embodiment of the present invention, the composition may inhibit the activity of mTORC1 (mammalian target of rapamycin complex 1).

In addition, the present invention provides a method for treating asthma, comprising: (S1) treating an astrocyte elevated gene-1 (AEG-1) expressing cell line with a test substance;

Measuring the expression or activity level of AEG-1 in the cell line of step S1 (S2); And

(S3) the expression or activity level of AEG-1 in step S2 is higher than that of the control without treatment of the test substance (S3).

In one embodiment of the present invention, the method of measuring the level of expression comprises the steps of RT-PCR, competitive RT-PCR, real time quantitative RT-PCR, (RT-PCR), RNase protection method, Northern blotting, and DNA chip technology.

In another embodiment of the present invention, the method of measuring the activity level may be selected from western blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radial immunodiffusion, Immunoprecipitation assays, complement fixation assays, immunofluorescence, immunofluorescence, immunohistochemical staining, immunohistochemical staining, immunohistochemical staining, immunohistochemistry, immunohistochemistry, immunohistochemistry, immunohistochemistry, And is characterized by being at least one method selected from the group consisting of immunochromatography, fluorescence activated cell sorter analysis and protein chip technology.

The present invention also provides a method for treating brain metastasis comprising administering the pharmaceutical composition to a subject.

In addition, the present invention provides the use of a composition comprising an astrocyte elevated gene-1 (AEG-1) protein or a nucleic acid molecule encoding the same, for the treatment of brain tumors.

The composition according to the present invention contains AEG-1 (astrocyte elevated gene-1) protein as an active ingredient, and the delayed effect of the AEG-1 treatment on the seizure of EEG was confirmed. Furthermore, it has been confirmed that AEG-1 can inhibit the granulocyte dispersion and the activity of mTORC1 (mammalian target of rapamycin complex 1), and thus it is possible to provide a more fundamental target therapeutic method in the prevention or treatment of epilepsy It is expected to be.

1 shows the results of immunohistochemical analysis of an increase in the expression of AEG-1 in hippocampal dentate gyrus of an animal model in which seizure persistence was induced by kainic acid (Scale bar, 200 μm and 100 μm. CON , Untreated control group; KA 7d, experimental group with 7 days of treatment with chitosan).
FIG. 2 is a graph showing the results of Western blot analysis (p = 0.015) showing that expression of AEG-1 is increased in hippocampal dentate gyrus of an animal model in which persimmon persistence is induced by kainic acid.
FIG. 3 is a diagram showing the results of double fluorescence staining for identifying an AEG-1 positive cell phenotype in a dentate granule cell layer of an animal model in which seizure persistence was induced by kainic acid (NeuN, neuronal nuclei, adult neuron marker, GFAP, glial fibrillary acidic protein, astrocytic marker.
Figure 4 shows the result of staining of AEG-1 expression induced by AAV-AEG-1 injection (Scale bar, 200 μm HA, Human influenza hemagglutinin, AEG-1 expression inducer marker, GFP, green fluorescent AEG-1, AEG-1-based gene construct, Mol, molecular layer of dentate gyrus, GCL, granule cell layer.
FIG. 5 is a graph showing the results of Western blot analysis to confirm whether expression of AEG-1 was induced by AAV-AEG-1 injection.
FIG. 6 is a graph showing the results of immunofluorescence labeling experiments (Scale bar, 50 .mu.m) confirming that target factors are specifically expressed in granule cells by AAV-AEG-1 injection.
FIG. 7 is a graph showing the results of Nissl staining of cerebral slices of normal rats (Scale bar, 200 μm) in order to confirm the change in the cellular structure of teeth after introduction of AAV-AEG-1 in hippocampal and granular cells.
FIG. 8 is a graph showing the results of comparing the control group and the control gene group and the experimental group by quantifying the width of the granule cell layer (Width of GCL) in order to confirm the change in the cellular structure of the teeth after introduction of AAV-AEG-1 in the hippocampal and granular cells (CON, contralateral side, EXP, ipsilateral side; NS, No significance).
FIG. 9 is a graph showing the results of confirming the change of mTORC1 activity after introduction of AAV-AEG-1 in hippocampal and granular cells.
FIG. 10 is a graph showing changes in AAV-AEG-1 introduced into hippocampal and granular cells in an animal model of brain trauma. A shows the result of confirming whether the development of the brain vaporization process is delayed by introduction KA, KA alone, KA-induced brain injury after treatment with GFP + KA and AAV-GFP; KA-induced brain injury after treatment with AAV-AEG-1; *** p <0.001), B (** p <0.01 and *** p <0.001, respectively) in the AAV-AEG-1-transfected mice compared with the control group and the control gene group (Width of GCL) AEG-AEG-1 in hippocampal dentate gyrus and granulocyte macrophage cells in an animal model of brain tumors, indicating that granular cell dispersion was observed , And D is the mammalian target of rapamycin c (mTORC1) induced by AAV-AEG-1 in hippocampal and granule cells (Scale bar, 200 μm. * p <0.05, ** p <0.01, and *** p <0.001;### p <0.001).

The present inventors confirmed that the delayed effect of AEG-1 treatment on the epileptic seizure by using an animal model in which brain growth was induced by kainic acid, and that the granulocyte dispersion and the activity of mTORC1 (mammalian target of rapamycin complex 1) The present invention has been completed on the basis thereof.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing or treating brain metastasis comprising an astrocytic elevated gene-1 (AEG-1) protein or a nucleic acid molecule encoding the same.

The AST-1 (astrocyte elevated gene-1) protein preferably comprises a protein having an amino acid sequence represented by SEQ ID NO: 1 or a protein encoded by a nucleotide sequence represented by SEQ ID NO: 2 and a functional equivalent of the protein . Is at least 70%, preferably at least 80%, more preferably at least 90%, even more preferably at least 70%, more preferably at least 90%, more preferably at least 90% Quot; refers to a protein having substantially the same physiological activity as a protein having the amino acid sequence represented by SEQ ID NO: 1, having a sequence homology of 95% or more.

In the AEG-1 protein of the present invention, not only a protein having a naturally occurring amino acid sequence but also an amino acid sequence variant thereof are also included in the scope of the present invention. A variant of an AEG-1 protein refers to a protein having a sequence that differs by deletion, insertion, non-conservative or conservative substitution, or a combination thereof, with the AEG-1 native amino acid sequence and one or more amino acid residues. Amino acid exchanges in proteins and peptides that do not globally alter the activity of the molecule are known in the art. The AEG-1 protein or its variants can be prepared by natural extraction or by synthesis (Merrifleld, J. Amer. Chem. Soc. 85: 2149-2156, 1963) or by DNA recombination methods Sambrook et al, Molecular Cloning, Cold Spring Harbor Laboratory Press, New York, USA, Second Edition, 1989).

The nucleic acid molecule encoding the AEG-1 protein may preferably consist of the nucleotide sequence shown in SEQ ID NO: 2, and variants of the nucleotide sequence are included within the scope of the present invention. Specifically, the nucleic acid molecule has a nucleotide sequence having a sequence homology of 70% or more, more preferably 80% or more, still more preferably 90% or more, and most preferably 95% or more, with the nucleotide sequence of SEQ ID NO: 1 . &Lt; / RTI &gt; "% Of sequence homology to polynucleotides" is ascertained by comparing the comparison region with two optimally aligned sequences, and a portion of the polynucleotide sequence in the comparison region is the reference sequence for the optimal alignment of the two sequences (I. E., A gap) relative to the &lt; / RTI &gt;

The nucleic acid molecule encoding the AEG-1 protein of the present invention may be in a form contained in a vector. The vector comprising the nucleic acid molecule encoding the AEG-1 protein may be a vector comprising a linear DNA, a plasmid vector, a vector comprising a viral expression vector, or a recombinant retrovirus vector, recombinant adenovirus ( a recombinant viral vector comprising an adenovirus vector, an adeno-associated virus (AAV) vector, a recombinant herpes simplex virus vector or a recombinant lentivirus vector is preferable, More preferably, it is an adeno-associated virus (AAV) vector, but is not limited thereto.

The "epilepticism", which is a preventive or therapeutic disease to be prevented or treated by the composition of the present invention, is a phenomenon in which some of the nerve cells generate seizure in a short time due to synchronization with abnormal abnormal excitement of the brain, Which is a serious neurological disorder accompanied by neurobiological, psychological, cognitive and social changes. In addition, unlike general brain neurological diseases, in which neurons regress or die, cognitive disorders, behavioral disorders, and the like, brain neurosis is characterized by a neurological disorder caused by abnormally excessive activation of nerve cells. In addition, hippocampal sclerosis, gonadal hyperplasia (Hippocampal sclerosis, etc.) in the hippocampus of cerebral regions, where pathological damage due to brain injury is evident due to excitotoxicity caused by hyperexcitability of abnormal neurons, gliosis, abnormal neurogenesis, cytoarchitectural abnormality of dentate granule cells, and aberrant syn- passic circuit. These pathologic events in the hippocampus may lead to chronic epileptic seizures and drug refractory intractable epilepsy that is not responsive to drug therapy as well as cognitive and memory disorders.

As used herein, the term &quot; prophylactic &quot; means any action that inhibits or delays the development of the brain metastasis by administration of the pharmaceutical composition according to the present invention.

As used herein, the term &quot; treatment &quot; means any action that improves or alters the symptoms of epilepsy by administration of the pharmaceutical composition according to the present invention.

In one embodiment of the present invention, it was confirmed that the occurrence of seizures could be delayed by treating the AEG-1 expression-increasing gene construct in an animal model in which brain growth was induced by kainic acid (see Example 4, Fig. 10A) . As a result of the above-mentioned findings, AEG-1 can effectively inhibit the granulocyte dispersion and the activity of mTORC1 (mammalian target of rapamycin complex 1) (See Example 4, Fig. 10D).

The pharmaceutical composition according to the present invention may contain a pharmaceutically acceptable carrier in addition to the active ingredient. The pharmacologically acceptable carriers are those conventionally used at the time of formulation and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose But are not limited to, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. Further, in addition to the above components, a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, and the like may be further included.

The pharmaceutical composition of the present invention may be administered orally or parenterally (for example, intravenously, subcutaneously, intraperitoneally or topically) depending on the intended method, and the dose may vary depending on the condition and the weight of the patient, The mode of administration, the route of administration, and the time, but may be appropriately selected by those skilled in the art.

The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, The sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, sequentially or concurrently with conventional therapeutic agents, and may be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

Specifically, the effective amount of the pharmaceutical composition of the present invention may vary depending on the age, sex, condition, body weight, the degree of absorption of the active ingredient in the body, the rate of inactivation and excretion, the type of disease, 100 to 500 mg / kg of body weight may be administered daily or every other day, or one to three times a day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.

The present invention also provides a health functional food composition for preventing or ameliorating epilepsy comprising astrocytic elevated gene-1 (AEG-1) as an active ingredient.

As used herein, the term "improvement" means all actions that at least reduce the degree of symptom associated with the condition being treated. At this time, the health functional food composition may be used either before or after the onset of the disease or simultaneously with or separately from the treatment for the prevention or improvement of epilepsy.

The term &quot; food composition &quot; as used in the present invention means a food composition comprising at least one of carrier, diluent, excipient and additives and being formulated into one selected from the group consisting of tablets, pills, powders, granules, powders, capsules, . Examples of foods that can be added to the composition of the present invention include various foods, powders, granules, tablets, capsules, syrups, drinks, gums, tea, vitamin complexes, and health functional foods. Examples of the additive that can be further included in the present invention include natural carbohydrates, flavors, nutrients, vitamins, minerals (electrolytes), flavors (synthetic flavors, natural flavors and the like), colorants, fillers, At least one component selected from alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, antioxidants, glycerin, alcohols, carbonating agents and fats can be used. Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. As the above-mentioned flavors, natural flavors (tautatin, stevia extract (for example, rebaudioside A and glycyrrhizin) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used. The composition according to the present invention can be used in various forms such as flavorings such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, colorants and heavies, factic acid and its salts, alginic acid and its salts, , a pH adjusting agent, a stabilizer, a preservative, a carbonating agent used in glycerin, an alcohol, a carbonated beverage, etc. In addition, the composition according to the present invention may contain flesh for the production of natural fruit juice and vegetable drinks . These ingredients may be used independently or in combination. Specific examples of the carrier, excipient, diluent and additives include, but are not limited to, lactose, dextrose, But are not limited to, sucrose, sorbitol, mannitol, erythritol, starch, acacia, calcium phosphate, alginate, gelatin, calcium phosphate, calcium silicate, microcrystalline cellulose, polyvinylquilolidone, cellulose, polyvinylpyrrolidone, methylcellulose, It is preferable to use at least one selected from the group consisting of sugar syrup, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.

In addition, the present invention provides a method for treating asthma, comprising: (S1) treating an astrocyte elevated gene-1 (AEG-1) expressing cell line with a test substance;

Measuring the expression or activity level of AEG-1 in the cell line of step S1 (S2); And

(S3) the expression or activity level of AEG-1 in step S2 is higher than that of the control without treatment of the test substance (S3).

The term "candidate substance" means a substance to be tested for its therapeutic activity for treating brain metastasis, and may include any molecule such as an extract, protein, oligopeptide, small organic molecule, polysaccharide, polynucleotide and a wide variety of compounds. Such candidate materials also include synthetic materials as well as natural materials.

Methods for measuring the expression level include RT-PCR, competitive RT-PCR, real-time quantitative RT-PCR, RNase protection assay RNase protection method, Northern blotting, and DNA chip technology. The present invention is not limited to these methods.

Methods for measuring the activity level include western blotting, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radial immunodiffusion, Ouchterlony immunodiffusion, Immunohistochemical staining, immunoprecipitation assay, complement fixation assay, immunofluorescence, immunochromatography, immunohistochemical staining, immunohistochemical staining, immunohistochemical staining, immunoprecipitation assay, complement fixation assay, A fluorescence activated cell sorter analysis, a protein chip technology, and the like, but the present invention is not limited thereto.

In another aspect of the present invention, the present invention provides a method for treating brain metastasis comprising the step of administering the above pharmaceutical composition to a subject. The term " individual "as used herein refers to a subject in need of treatment of a disease, and more specifically refers to a mammal such as a human or non-human primate, mouse, dog, cat, horse, do.

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the following examples.

[ Example ]

Example  One. Evaporation of the brain  Animal model hippocampus In the teeth AEG -1 expression

1-1. Evaporation of the brain  Animal modeling

Adult male C57BL / 6 mice of 8 weeks old were purchased from Daehan Biolink (Eumseong, Korea) and used as a control group without intracerebral angiogenesis. As experimental groups, chloral hydrate (chloral (David Kopf Instrument, Tujunga, CA.) after anesthesia by intraperitoneal administration of ip (hydrate, 360 mg / kg; Sigma, St. Louis, MO.). Kainic acid (KA; 0.2 μg in 2 μL phosphate-buffered saline (PBS); Sigma] was added to the hippocampus of each mouse according to a known method (Jeong et al., 2015; Jang et al., 2016) The right hippocampus (AP: -0.20 cm; ML: -0.16 cm; DV: -0.15 cm, relative to bregma) using a 10 μl Hamilton syringe (30S needle) attached to a syringe pump (KD Scientific, New Hope, PA. , Franklin and Paxinos, 2004. After injection, the needle was kept for an additional 5 minutes before slow recovery to produce an animal model of epileptic seizure. All experiments were performed according to protocols and guidelines of the Animal Ethics Committee of Kyungpook National University Respectively.

1-2. Immunohistochemical staining ( Immunohistochemical  staining)

Immunohistochemical staining was performed by modifying a known experimental method (Kim et al., 2005; Kim et al., 2011; Kim et al., 2012). Euthanasia was performed on the seventh day after treatment with kainic acid in each of the mice of Example 1-1, and the tissues were fixed by performing a perfusion perfusion, and the brain tissue was sectioned to a thickness of 30 탆. (AEG-1, 1: 500; Invitrogen, Camarillo, CA.) was used as the primary antibody for 48 h. Respectively. After washing with PBS, the cells were incubated with secondary antibody and treated with avidin-biotin complex kit (Vector Laboratories, Burlingame, CA.). The signal was detected by incubating the tissue section with 0.5 mg / ml 3,3'-diaminobenzidine (Sigma) dissolved in 0.1 M PB containing 0.003% H ₂ O ₂ . The dyed samples were analyzed using a bright-field microscope (Carl Zeiss, Gottingen, Germany).

In addition, for immunofluorescence labeling, sections of brain tissue were washed and incubated with anti-AEG-1 (1: 500; Invitrogen) and anti-neuronal nuclei (NeuN, 1: 1000; Millipore, Bedford, MA. ) and anti-glial fibrillary acidic protein (GFAP, 1: 1000; Millipore) antibodies. The next day, tissue sections were washed and incubated with Cy3 conjugated anti-rabbit IgG (1: 200; Millipore) and FITC-conjugated anti-mouse IgG (1: 200; Millipore) for 1 hour and washed again. This was mounted with a Vectashield mounting medium (Vector). Dyed samples were observed using a confocal microscope (LSM700, Carl Zeiss, Germany).

1-3. Western blot analysis

The mice of Example 1-1 were treated with kainic acid by modifying a known experimental method (Kim et al., 2005; Kim et al., 2011; Kim et al., 2012) , And hippocampal tissues were extracted. The harvested hippocampal tissue was homogenized and centrifuged to separate the supernatant (4 ° C, 15 min, 14000 g). Protein concentration was determined using a bicinchoninic acid assay kit (BCA kit; Bio-Rad Laboratories, Hercules, Calif., USA) and proteins were separated by SDS-PAGE (Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis). The separated proteins were transferred to the membrane using an electrophoretic transfer system (Bio-Rad Laboratories) and incubated with primary antibodies [anti-AEG-1 (1: 500; Invitrogen), anti-β-actin Signaling, Beverly, MA.) At 4 ° C for one day. The cells were then reacted with secondary antibodies (Amersham Biosciences, Piscataway, NJ, USA) and developed with ECL Western blot detection reagents (Amersham Biosciences). For quantitative analysis, the density of each protein was measured using a computer program Image gauge 4.0 (FUJIFILM Science Lab).

1-4. Statistical analysis

All values were expressed as mean ± standard error of the mean (SEM) using the Sigma plot 12.0 program. Multiple comparisons were performed using one-way analysis of variance (ANOVA) using the Tukey post-test.

1-5. Check the result

As shown in Fig. 1 showing results of immunohistochemistry, it was confirmed that the hippocampal tooth treated with kainic acid showed stronger expression of AEG-1 as compared with the control group, Similar to the blot analysis results, the hippocampal tissues of animals treated with kainic acid showed higher levels of AEG-1 expression than those of the untreated controls in Fig.

The results of the double fluorescent staining for the identification of AEG-1 positive cell phenotype in the dentate granule cell layer are shown in FIG. 3 (NeuN, neuronal nuclei, adult neuron marker; GFAP, glial fibrillary acidic protein, astrocytic marker). As can be seen in FIG. 3, AEG-1 expression was prominent in the dentate granule cell layer in which hippocampal-treated hippocampal granules had undergone decidualization (Fig. 3, left) and active astrocytes AEG-1 expression was also observed in the reactive astrocyte (Fig. 3, right).

Example  2. AAV - AEG -1 production

2-1. pBL - AEG -1 recombinant vector production and AAV - AEG -1 production

AEG-1 gene was introduced into the pBL plasmid (HA-tag) to prepare a pBL-AEG-1 recombinant vector into which the AEG-1 gene was introduced. Adeno-associated virus (AAV) -AEG-1 was constructed at the University of North Carolina Vector Core and the genetic trait was 9.4 × 10 ¹² viral genomes / ml. Activated GFP (green fluorescent protein) was subcloned into the same viral backbone and used as a control.

2-2. Adult mouse hippocampus through brain surgery AAV - AEG -1 injection and expression confirmation

8-week-old adult male C57BL / 6 mice (Daehan Biolink) were anesthetized by administering chloral hydrate (360 mg / kg; Sigma) and placed in a stereotaxic frame. A 10 μl Hamilton syringe (30S needle) attached to a pneumatic pump (KD Scientific) containing AAV-AEG-1 was applied to the hippocampal area of each mouse using a conventional method (Jeon et al., 2015) (Franklin and Paxinos, 2004) were injected into the right hippocampal tooth (AP: -0.20 cm; ML: -0.14 cm; DV: -0.17 cm, relative to bregma). After injection, the needle was held for an additional 5 minutes before slowly withdrawing. At this time, 2.0 μl of viral vector suspension was injected at a rate of 0.1 μl / min for 20 minutes. Three weeks after injection of AAV-GFP and AAV-AEG-1 into normal adult mouse hippocampal area, each mouse was euthanized and the expression pattern of AEG-1 was confirmed by immunohistochemical staining and western blot analysis. AEG-1 expression was detected by immunohistochemical staining using primary antibody (anti-HA (1: 100; Cell-signaling)]. In immunofluorescence labeling experiments, primary antibodies (anti-HA (1: 100; Cell-signaling), anti-NeuN (1: 1000; Millipore), anti- GFAP (1: 500; Invitrogen). Western blot analysis was performed using the anti-AEG-1 antibody (1: 500, Invitrogen) , anti-HA (1: 100; Cell-signaling), anti-GFP (1: 100; Millipore) and anti-β-actin (1: 4000, Cell Signaling).

2-3. Check the result

In Example 2, AEG-1 expression was induced in hippocampal skeletal granule cells of normal rats by introduction of AEG-1-based gene construct, AAV-AEG-1.

As a result, as shown in Fig. 4, it was confirmed that HA (human influenza hemagglutinin) was expressed in the dental granule cell 3 weeks after the injection of AAV-AEG-1, and AEG-1 expression was induced.

The results are similar to those of the Western blot analysis shown in FIG. 5. In FIG. 5, AEG-1 showed the strongest expression in the lane injected with AAV-AEG-1, Expression was also observed.

Further, as can be seen from the immunofluorescence labeling experiment results of FIG. 6, it was confirmed that the target factors were specifically expressed in the granule cells.

That is, it can be confirmed that the introduction of AAV-AEG-1 increases the expression level of AEG-1 as compared with that of control mice (CON) or control gene group (GFP) which are not introduced.

Example  3. Normal hippocampus Teia  of mine AEG -1 gene introduction Granular cell dispersion  Confirmation of occurrence

3-1. Cresyl  Through violet staining Granular cell dispersion  Determination of occurrence and change of related factor activity

With reference to the known experimental method (Jeong et al., 2015; Jang et al., 2016; Park et al., 2016), a 30 μm thick coronal brain section of the brain was prepared. The cerebral sections were attached to the slides and stained with 0.5% cresyl violet (Sigma). The degree of granulocyte dispersion (GCD) was measured by comparing the average width of the granule cell layer at the inner 1/4 point and the midpoint of the granule cell layer (GCL) in the dentate gyrus (DG) The average width of the horny tooth and granule cell layer treated with kainic acid was compared with the mean width of the granule cell layer of the teeth and analyzed as a percentage. Western blot analysis was performed to determine the activity of mTORC1 (mammalian target of rapamycin complex 1) associated with granulocyte dispersion. To determine the activity of mTORC1, anti-phospho-4E-BP1 (T37 / Cell-signaling), anti-4E-BP1 (1: 1000; Cell-signaling) and anti-β-actin (1: 4000, Cell Signaling).

3-2. Check the result

As a result of Nissl staining of the cerebral slices shown in FIG. 7, the change in skeletal cell structure was not observed, and the cell structure of AAV-AEG-1-transfected rat and that of control group were not changed. The width of the granule cell layer (Width of GCL) was quantified and compared with the control group. As shown in Fig. 8, no significant difference was observed in the granulosa cell layer width of AAV-AEG-1-transfected rats and the control group.

FIG. 9 shows the result of confirming whether mTORC1 activity, which is a factor related to granulocyte dispersion, changes after introduction of AAV-AEG-1. As shown in FIG. 9, the degree of T37 / 46 phosphorylation of 4E- As a result, there was no change in the activity of mTORC1 in the AAV-AEG-1-injected experimental group as compared with the normal control (CON) and the control gene treatment group (GFP).

That is, even when AAV-AEG-1 is introduced into normal rats, it does not cause abnormal cell structure changes such as cell granule disintegration.

Example  4. Evaporation of the brain  Hippocampus in animal model Teia  of mine AEG -1 introduction Antepicture  Check the effect

4-1. Kainic acid  By treatment Epilepsy  Check for delayed seizure effects

3 weeks after injection of AAV-GFP and AAV-AEG-1 into the right hippocampal area of a normal mouse as in the experimental method of Example 2-2, kainic acid was treated in the hippocampus to induce an epileptic seizure. Kainic acid-treated mice were photographed for 6 hours and measured the time of seizure onset by treatment with kainic acid to confirm the delayed effect of latency of seizure onset by AAV-AEG-1 administration Respectively. Behavioral seizure stages are identified in five stages, with each stage being stage 1, facial movement; Step 2, head nodding and myoclonic twitching; Step 3, forelimb clonus with lordotic posture in a dorsal posture; Step 4, forelimb clonus with reared posture in posterior position; There is a behavioral pattern of tonic-clonic seizure without postural control (Macias et al., 2013; Racine, 1972). In the present example, the onset of seizures was set at the point of time when three types of seizure-induced seizure types (forelimb clonus with lordotic posture) were observed in the treatment with kainic acid, The time of occurrence was recorded.

4-2. hippocampus Teia Granule cell  of mine AEG -1 introduction Granular cell dispersion  Generation and inhibition of related factors

Using the experimental methods described in Examples 1-2 and 3-1, granulocyte dispersion and the inhibitory effect of related factors were confirmed. First, AEG-1 gene was introduced into hippocampal and granular cells of mice treated with kainic acid to induce brain-spontaneous evaporation, and granulocyte dispersion and expression of related factors were confirmed by brain-spontaneous evaporation. 4E-BP1, a key marker of granulocyte dispersion, was detected by immunohistochemical staining. The number of cells showing a positive reaction of p-4E-BP1 in the hippocampal dentine of each mouse was expressed as a percentage And analyzed.

4-3. Check the result

In Example 4, it was confirmed that the introduction of AEG-1 into the hippocampal and granular cells of the epileptic animal model delayed the development of the brain metastasis and inhibited the granular cell dispersion.

FIG. 10A shows the result of confirming whether the epileptic seizure was delayed when the hippocampus was treated with caudate after 3 weeks of introduction of AAV-AEG-1. As shown in Fig. 10A, it was confirmed that the time of onset of brain metastasis induced by chitosan was significantly delayed in AAV-AEG-1-transfected mice.

As shown in FIG. 10B, the AAV-AEG-1-transfected rat was compared with the control group and the control gene group in terms of the width of granule cell layer (Width of GCL) It was confirmed that the occurrence of decentralization remarkably decreased. Similar to the above results, it can be confirmed from the result of staining of the cerebral slices shown in Fig. 10C that the granular cell dispersion phenomenon hardly occurs in the rats into which AAV-AEG-1 has been introduced.

The results of p-4E-BP1 staining in the dentate granule cell layer are also shown in Fig. 10D. As a result, it was confirmed that the number and expression level of p-4E-BP1-positive cells in the granulosa cell layer into which AEG-1 was introduced were significantly reduced.

From the results of the above examples, it can be seen that introduction of AEG-1, which is an effective component of the composition of the present invention, significantly inhibits the occurrence of granular cell decidua associated with the brain tremor. From this, it can be seen that the AEG- It was confirmed that the effect of treatment of brain metastasis was excellent.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive.

<110> Kyungpook National University Industry-Academic Cooperation Foundation          University-Industry Cooperation Group of Kyung Hee University <120> Composition comprising astrocyte elevated gene-1 for preventing          or treating epilepsy <130> MP16-436 <160> 2 <170> KoPatentin 3.0 <210> 1 <211> 582 <212> PRT <213> Homo sapiens <400> 1 Met Ala Ala Arg Ser Trp Gln Asp Glu Leu Ala Gln Gln Ala Glu Glu   1 5 10 15 Gly Ser Ala Arg Leu Arg Glu Met Leu Ser Val Gly Leu Gly Phe Leu              20 25 30 Arg Thr Glu Leu Gly Leu Asp Leu Gly Leu Glu Pro Lys Arg Tyr Pro          35 40 45 Gly Trp Val Ile Leu Val Gly Thr Gly Ala Leu Gly Leu Leu Leu Leu      50 55 60 Phe Leu Leu Gly Tyr Gly Trp Ala Ala Ala Cys Ala Gly Ala Arg Lys  65 70 75 80 Lys Arg Arg Ser Pro Pro Arg Lys Arg Glu Glu Ala Ala Ala Val Pro                  85 90 95 Ala Ala Ala Pro Asp Asp Leu Ala Leu Leu Lys Asn Leu Arg Ser Glu             100 105 110 Glu Gln Lys Lys Lys Asn Arg Lys Lys Leu Ser Glu Lys Pro Lys Pro         115 120 125 Asn Gly Arg Thr Val Glu Val Ala Glu Gly Glu Ala Val Arg Thr Pro     130 135 140 Gln Ser Val Thr Ala Lys Gln Pro Pro Glu Ile Asp Lys Lys Asn Glu 145 150 155 160 Lys Ser Lys Lys Asn Lys Lys Lys Ser Lys Ser Asp Ala Lys Ala Val                 165 170 175 Gln Asn Ser Ser Arg His Asp Gly Lys Glu Val Asp Glu Gly Ala Trp             180 185 190 Glu Thr Lys Ile Ser His Arg Glu Lys Arg Gln Gln Arg Lys Arg Asp         195 200 205 Lys Val Leu Thr Asp Ser Gly Ser Leu Asp Ser Thr Ile Pro Gly Ile     210 215 220 Glu Asn Thr Ile Thr Val Thr Thr Glu Gln Leu Thr Thr Ala Ser Phe 225 230 235 240 Pro Val Gly Ser Lys Lys Asn Lys Gly Asp Ser His Leu Asn Val Gln                 245 250 255 Val Ser Asn Phe Lys Ser Gly Lys Gly Asp Ser Thr Leu Gln Val Ser             260 265 270 Ser Gly Leu Asn Glu Asn Leu Thr Val Asn Gly Gly Gly Trp Asn Glu         275 280 285 Lys Ser Val Lys Leu Ser Ser Gln Ile Ser Ala Gly Glu Glu Lys Trp     290 295 300 Asn Ser Val Ser Pro Ala Ser Ala Gly Lys Arg Lys Thr Glu Pro Ser 305 310 315 320 Ala Trp Ser Gln Asp Thr Gly Asp Ala Asn Thr Asn Gly Lys Asp Trp                 325 330 335 Gly Arg Ser Serp Ser Asp Arg Ser Ile Phe Ser Gly Ile Gly Ser Thr             340 345 350 Ala Glu Pro Val Ser Gln Ser Thr Thr Ser Asp Tyr Gln Trp Asp Val         355 360 365 Ser Arg Asn Gln Pro Tyr Ile Asp Asp Glu Trp Ser Gly Leu Asn Gly     370 375 380 Leu Ser Ser Ala Asp Pro Asn Ser Asp Trp Asn Ala Pro Ala Glu Glu 385 390 395 400 Trp Gly Asn Trp Val Asp Glu Glu Arg Ala Ser Leu Leu Lys Ser Gln                 405 410 415 Glu Pro Ile Pro Asp Asp Gln Lys Val Ser Asp Asp Asp Lys Glu Lys             420 425 430 Gly Glu Gly Ala Leu Pro Thr Gly Lys Ser Lys Lys Lys Lys Lys Lys Lys         435 440 445 Lys Lys Lys Gln Gly Glu Asp Asn Ser Thr Ala Gln Asp Thr Glu Glu     450 455 460 Leu Glu Lys Glu Ile Arg Glu Asp Leu Pro Val Asn Thr Ser Lys Thr 465 470 475 480 Arg Pro Lys Gln Glu Lys Ala Phe Ser Leu Lys Thr Ile Ser Thr Ser                 485 490 495 Asp Pro Ala Glu Val Leu Val Lys Asn Ser Gln Pro Ile Lys Thr Leu             500 505 510 Pro Pro Ala Thr Ser Thr Glu Pro Ser Val Ile Leu Ser Lys Ser Asp         515 520 525 Ser Asp Lys Ser Ser Ser Gln Val Pro Pro Ile Leu Gln Glu Thr Asp     530 535 540 Lys Ser Lys Ser Asn Thr Lys Gln Asn Ser Val Pro Pro Ser Gln Thr 545 550 555 560 Lys Ser Glu Thr Ser Trp Glu Ser Pro Lys Gln Ile Lys Lys Lys Lys                 565 570 575 Lys Ala Arg Arg Glu Thr             580 <210> 2 <211> 1746 <212> DNA <213> Homo sapiens <400> 2 atggctgcac ggagctggca ggacgagctg gcccagcagg ccgaggaggg ctcggcccgg 60 ctgcgggaaa tgctctcggt cggcctaggc tttctgcgca ccgagctggg cctcgacctg 120 gggctggagc cgaaacggta ccccggctgg gtgatcctgg tgggcactgg cgcgctcggg 180 ctgctgctgc tgtttctgct gggctacggc tgggccgcgg cttgcgccgg cgcccgcaaa 240 aagcggagga gcccgccccg caagcgggag gaggcggcgg ccgtgccggc cgcggccccc 300 gacgacctgg ccttgctgaa gaatctccgg agcgaggaac agaagaagaa gaaccggaag 360 aaactgtccg agaagcccaa accaaatggg cggactgttg aagtggctga gggtgaagct 420 gttcgaacac ctcaaagtgt aacagcaaag cagccaccag agattgacaa gaaaaatgaa 480 aagtcaaaga aaaataagaa gaaatcaaag tcagatgcta aagcagtgca aaacagttca 540 cgccatgatg gaaaggaagt tgatgaagga gcctgggaaa ctaaaattag tcacagagag 600 aaacgacagc agcgtaaacg tgataaggtg ctgactgatt ctggttcatt ggattcaact 660 atccctggga tagaaaatac catcacagtt accaccgagc aacttacaac cgcatcattt 720 cctgttggtt ccaagaagaa taaaggtgat tctcatctaa atgttcaagt tagcaacttt 780 aaatctggaa aaggagattc tacacttcag gtttcttcag gattgaatga aaacctcact 840 gtcaatggag gaggctggaa tgaaaagtct gtaaaactct cctcacagat cagtgcaggt 900 gaggagaagt ggaactccgt ttcacctgct tctgcaggaa agaggaaaac tgagccatct 960 gcctggagtc aagacactgg agatgctaat acaaatggaa aagactgggg aaggagttgg 1020 agtgaccgtt caatattttc tggcattggg tctactgctg agccagtttc tcagtctacc 1080 acttctgatt atcagtggga tgttagccgt aatcaaccct atatcgatga tgaatggtct 1140 gggttaaatg gtctgtcttc tgctgatccc aactctgatt ggaatgcacc agcagaagag 1200 tggggcaatt gggtagacga agaaagagct tcacttctaa agtcccagga accaattcct 1260 gatgatcaaa aggtctcaga tgatgataaa gaaaagggag agggagctct tccaactggg 1320 aaatccaaaa agaaaaaaaa gaaaaagaag aagcaaggtg aagataactc tactgcacag 1380 gacacagaag aattagaaaa agagattaga gaagaccttc cagtgaatac ctctaaaacc 1440 cgtccaaaac aggaaaaagc tttttccttg aagaccataa gcactagtga tccagccgaa 1500 gtactcgtca aaaatagcca gcctatcaag actcttccac ctgctacttc taccgagcca 1560 tctgtaatct tatcaaaaag tgattctgac aagagctctt cccaagtgcc gccaatacta 1620 caagagacag ataaatccaa gtcaaatacc aagcaaaata gtgtgcctcc ttcacagacc 1680 aagtctgaaa ctagctggga atctcccaaa caaataaaaa agaagaaaaa agccagacga 1740 gaaacg 1746

Claims (12)

1. A pharmaceutical composition for preventing or treating brain metastasis comprising, as an active ingredient, a nucleic acid molecule encoding an AEG-1 (astrocyte elevated gene-1) protein or an AEG-1 protein,
The composition inhibits the granulation of the granule cells,
Wherein said composition inhibits the activity of mTORC1 (mammalian target of rapamycin complex 1).
The method according to claim 1,
Wherein the AEG-1 protein comprises the amino acid sequence of SEQ ID NO: 1.
The method according to claim 1,
Wherein the nucleic acid molecule encoding the AEG-1 protein comprises the nucleotide sequence of SEQ ID NO: 2.
The method according to claim 1,
Wherein the nucleic acid molecule encoding the AEG-1 protein is contained in a vector.
5. The method of claim 4,
Wherein said vector is at least one selected from the group consisting of linear DNA, plasmid DNA and recombinant viral vectors.
6. The method of claim 5,
Wherein the recombinant viral vector is an adeno-associated virus (AAV).
delete delete 1. A health functional food composition for improving brain metastasis comprising an AEG-1 (astrocyte elevated gene-1) protein or a nucleic acid molecule encoding an AEG-1 protein as an active ingredient,
The composition inhibits the granulation of the granule cells,
Wherein said composition inhibits the activity of mTORC1 (mammalian target of rapamycin complex 1). delete delete delete

Images